Autologous fibrin acts as an excellent system of gradual local release of growth factors, largely responsible for the clinical efficacy of the treatment.
Endoret® (PRGF®) technology is specifically indicated for arthrosis. Its application can slow the progress of the disease, reduce pain and inflammation and improve patient mobility and quality of life, with no side effects.
Endoret® (PRGF®) is the only plasma rich in growth factors that have been proven to be effective in two clinical trials at level one evidence.
Endoret® (PRGF®) is indicated as a treatment for arthrosis of the hips, knees, and hands. The degrees of arthrosis to be treated are: grade I, II or III (according to the Ahlback scale)
Delays progression of the arthrosis
Reduces inflammation and pain effectively
Lessens joint rigidity
Improves the patient's function and mobility
Improves the patient's quality of life